Showing 681-690 of 1321 results for "".
- FDA Approves Sol-Gel Technologies' and Galderma's Epsolay for Rosaceahttps://practicaldermatology.com/news/fda-approves-sol-gel-technologies-and-galdermas-epsolay-for-rosacea/2461170/The FDA has approved Sol-Gel Technologies' Epsolay, a proprietary cream formulation of benzoyl peroxide, 5%, for the treatment of inflammatory lesions of rosacea in adults. The benzoyl peroxide in Epsolay is encapsulated within silica-based patented microcapsules. The silica-based s
- FDA Accepts Revance's BLA Resubmission for DaxibotulinumtoxinAhttps://practicaldermatology.com/news/fda-accepts-revances-bla-resubmission-for-daxibotulinumtoxina/2461167/The U.S. Food and Drug Administration (FDA) accepted Revance’s Biologics License Application (BLA) resubmission for DaxibotulinumtoxinA for Injection for the treatment of moderate to severe glabellar lines. The FDA designated the BLA as a Class 2 resubmission, which has a six-mont
- Castle's Non-Invasive Gene Expression Profile Test Can Predict Response to Systemic Therapy in Patients with Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/castles-gene-expression-profile-test-can-predict-response-to-systemic-therapy-in-patients-with-inflammatory-skin-diseases/2461163/Castle Biosciences, Inc.’s non-invasive skin scraping technique produces sufficient ribonucleic acid (RNA) to assess reproducible gene expression for its inflammatory skin disease pipeline test, according to a poster was presented at the 4th Annual Revolutionizing Atopic Der
- Country Music Artist Ashley Barron Named National Scleroderma Foundation’s Celebrity Ambassadorhttps://practicaldermatology.com/news/country-music-artist-ashley-barron-named-national-scleroderma-foundations-celebrity-ambassador/2461155/Country music artist Ashley Barron is the National Scleroderma Foundation’s official Celebrity Ambassador. Barron was diagnosed with scleroderma at age five. At that time, her family had never heard of the disease. Now as Celebrity Ambassador, Barron is working to represent
- Blueberry Extract May Improve Wound Healinghttps://practicaldermatology.com/news/blueberry-extract-may-improve-wound-healing/2461152/Treating wounds with an extract taken from wild blueberries may improve healing, according to a new study presented at the American Physiological Society’s annual meeting at Experimental Biology 2022. Researchers from the University of Maine previously found that a phenolic extrac
- Opzelura Shows Benefit in 52-Week Phase 3 Vitiligo Studyhttps://practicaldermatology.com/news/opzelura-shows-benefit-in-52-week-phase-3-vitiligo-study/2461139/New 52-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Incyte's topical JAK1/JAK2 inhibitor ruxolitinib cream (Opzelura™) in adolescent and adult patients with nonsegmental vitiligo show that twice daily application was
- DERMWIRE Exclusive: FDA Clears Cutera’s AviClear Acne Devicehttps://practicaldermatology.com/news/dermwire-exclusive-fda-clears-cuteras-aviclear-acne-device/2461124/The U.S. Food and Drug Administration has cleared granted 510(k) clearance to Cutera’s AviClear acne device. This is the first energy device to receive a nod for the treatment of mild, moderate, and severe acne. AviClear targets acne at the source by selec
- Jeune Aesthetics Announces Positive Clinical Phase 1 Efficacy Results for KB301https://practicaldermatology.com/news/jeune-aesthetics-announces-positive-clinical-phase-1-efficacy-results-for-kb301/2461119/Aesthetics, Inc.’s KB301 demonstrated promise in proof-of-concept in the Phase 1 PEARL-1 study. Specifically, Cohort 2 of this trial evaluated KB301 for the improvement of fine lines and skin texture in the lower and upper cheek, and for improvement in skin thickness in
- Cynosure Partners with Jeisys Medical Japanhttps://practicaldermatology.com/news/cynosure-partners-with-jeisys-medical-japan/2461114/Cynosure LLC’s subsidiary Cynosure KK has entered into a distribution partnership with Jeisys Medical KK, a subsidiary of Jeisys Medical Inc. in Japan. Under the terms of the agreement, Jeisys Medical will have exclusive distribution rights for products within Cynosure&
- It's Grant Season: NEA Announces 2022 Eczema Research Grant Cyclehttps://practicaldermatology.com/news/its-grant-season-nea-announces-2022-eczema-research-grant-cycle-1/2461109/The National Eczema Association's (NEA) 2022 research grant cycle is now open, with awards totaling $760,000. Applications must be received by June 1, 2022, at 5 p.m. PDT, and recipients will be announced in October 2022. As the largest private nonprofi